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- In this first-in-human, phase 1 study, recombinant ADAMTS-13 was safe, non-
immunogenic and well tolerated in patients with congenital TTP. 
-  Recombinant ADAMTS-13 demonstrated a PK profile comparable to plasma infusion 
studies, and showed evidence of pharmacodynamic activity. 
 




Safety, tolerability and pharmacokinetics of recombinant ADAMTS-13 (rADAMTS-13; 
BAX 930; SHP655) were investigated in 15 patients diagnosed with severe congenital 
ADAMTS-13 deficiency (plasma ADAMTS-13 activity < 6%) in a prospective phase 1, 
first-in-human, multicenter dose escalation study. BAX 930 was well tolerated, no 
serious adverse events occurred, and no anti-ADAMTS-13 antibodies were observed.  
Following single dose administration of BAX 930 at 5, 20, or 40 U/kg body weight to 
adolescents and adults, there was approximate dose proportionality with respect to Cmax 
and AUC. Dose related increases of individual ADAMTS-13:Ag and activity were 
observed and reached a maximum within 1 hour. With escalating BAX 930 doses 
administered, a dose-dependent persistence of ADAMTS-13-mediated VWF cleavage 
products and reduced VWF multimeric size were observed. This study demonstrated that 
pharmacokinetic parameters of BAX 930 were comparable to those estimated in previous 
plasma infusion studies and provided evidence of pharmacodynamic activity.  The study 








The plasma metalloprotease, ADAMTS-13 (a disintegrin and metalloproteinase with a 
thrombospondin type 1 motif, member 13), is a constitutively active enzyme that cleaves 
von Willebrand factor (VWF) at the Tyr1605-Met1606 bond in the A2 domain, an 
otherwise cryptic site rendered susceptible, by the application of shear stress, to regulate 
the size of VWF multimers.1  VWF is a multimeric glycoprotein synthesized principally 
by vascular endothelial cells.2 The inability to cleave ultra-large (UL) VWF multimers 
into smaller forms due to congenital or acquired ADAMTS-13 deficiency results in 
thrombotic thrombocytopenic purpura (TTP), a rare potentially fatal disorder of the 
microcirculation caused by increased binding of platelets to UL VWF.3  The congenital 
form of TTP (cTTP, previously termed hereditary TTP or Upshaw-Schulman syndrome) 
is an ultra rare, though likely underestimated condition with prevalence of  approximately 
1 case per million.4;5 It exhibits an autosomal recessive mode of inheritance caused by 
homozygous or compound heterozygous mutations in both ADAMTS-13 alleles on 
chromosome 9.6 The nature of the mutations is diverse and includes single amino acid 
missense substitution (approximately 60%) as well as nonsense, frame-shift, splice site 
mutations, and deletions and insertions (collectively approximately 40%).1,7,8,9 
The principal pathophysiology arises from platelet aggregates in the microcirculation 
affecting critical organs including the brain, heart and kidneys. TTP crises are associated 
with cerebral vascular incidents in at least 30% of patients, with a risk of neurologic 
sequelae in approximately 20% of patients.10 Acute renal failure has been reported in 
11% of patients with severe cTTP,11 and chronic, possibly progressive renal involvement 
is often seen. Sudden cardiac death due to myocardial infarction, heart failure and 
arrhythmia has also been reported.12 
Although considered a monogenetic disorder, the clinical presentation of cTTP is 
variable. Symptoms develop soon after birth in some patients, whereas others remain 
asymptomatic until the second or third decade of life. This phenotypic variability is 
thought to be related to the causative mutations and the level of plasma ADAMTS-13 
activity.13;14 In the newborn, cTTP typically presents as neonatal jaundice and 
thrombocytopenia,3 while in early childhood, symptomatic episodes are often associated 
with intercurrent infections or vaccinations.  Among cTTP patients presenting with a first 
TTP episode later in life, pregnancy is often the inciting event.15  Intrauterine fetal death 
is common in cTTP patients who do not receive regular plasma therapy throughout 
pregnancy.16;17 Other precipitants associated with increased VWF levels, such as 
infection, surgery and alcohol binge drinking provide additional triggers for acute TTP 
events.18-22 Despite the wide range of ages of the first TTP event, most cTTP patients 
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subsequently demonstrate a chronic, relapsing course and require prophylactic treatment 
to prevent long-term neurological, renal and other sequelae.  
There are no drugs currently approved for the specific treatment of cTTP. Acute TTP 
episodes are generally treated with infusions of fresh frozen plasma (FFP) or 
solvent/detergent (S/D) treated plasma, typically 10-20 mL/kg body weight (BW). Some 
intermediate purity FVIII:VWF concentrates have been shown to contain low levels of 
ADAMTS-13 and have been used as an alternative treatment in select patient 
populations.23 Although the half-life of infused plasma ADAMTS-13 was found to be 2-4 
days,24 prophylaxis with 10-15ml plasma /kg body weight every 2-3 weeks has been 
shown to be effective in preventing acute episodes in the majority of TTP patients.6,25,26  
While the treatment of TTP via plasma infusions is generally effective, the therapy is 
frequently complicated by allergic and anaphylactic reactions or volume overload.27 
Plasma infusions also carry risks of infection due to blood-borne pathogens. In addition, 
plasma infusions carried out in the hospital or outpatient settings are burdensome, time 
consuming, and can be stressful for younger patients. As such, the development of a 
recombinant ADAMTS-13 (BAX 930; SHP 655; rADAMTS-13) represents a potential 
new therapeutic option to improve the current standard of care. 
In this Phase 1, first-in-human study, we investigated the safety, including 
immunogenicity, tolerability and pharmacokinetics of rADAMTS-13 in patients 




This was a prospective, open-label, multicenter, first-in-human dose escalation study on 
safety, immunogenicity, tolerability and pharmacokinetics (PK) of BAX 930 in patients 
diagnosed with cTTP assigned to one of three dose cohorts, receiving a single dose of 
BAX 930 at 5, 20 or 40 U/kg body weight (BW), where one unit is approximately 
equivalent to the ADAMTS-13 activity in 1 mL of plasma.  The study comprised two 
dose escalation steps. Fifteen patients were enrolled (out of 16 screened:  one was unable 
to participate due to a scheduling conflict) and dosed sequentially. Subjects were 
recruited to the next higher dose level only after short-term safety had been demonstrated 
and reviewed by an independent Data Monitoring Committee (DMC) at the preceding 
dose level.  The study was approved by the responsible Ethics Committees or institutional 
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review boards and regulatory authorities.  The study was registered on 
www.clinicaltrials.gov under the number NCT02216084. All participants gave written 
informed consent.  Data were analyzed by biostatisticians at Shire and Quintiles; all 
authors had access to primary clinical trial data.   
Patients  
The principal inclusion criteria consisted of a documented diagnosis of severe congenital 
ADAMTS-13 deficiency (baseline plasma ADAMTS-13 activity <6%) confirmed by 
genetic testing, ages 12-65 years, and the absence of severe TTP symptoms at the time of 
screening. This included stable laboratory parameters (platelet count >100 x 109/L, LDH 
<3 times ULN [upper limit of normal]).  Evidence of end organ damage such as stroke, 
heart, renal disease or abnormal liver function tests were further exclusions to study 
enrollment. Patients with a medical history or presence of functional neutralizing 
ADAMTS-13 inhibitor at screening, or a medical history of immunological or 
autoimmune disorders, or significant neurological events were excluded. A sample size of 
14 was selected on the basis of feasibility. 
Study drug and treatments 
BAX 930 is a fully glycosylated recombinant human ADAMTS-13 protein produced in a 
Chinese hamster ovary (CHO) mammalian expression system in a plasma protein-free 
milieu.  The cell culture and purification processes used in the manufacture of BAX 930 
do not employ additives of human or animal origin. The purification process of BAX 930 
is based on chromatography using conventionally available resins including anion 
exchange, hydroxyapatite, mixed mode (hydrophobic interaction) and cation exchange. In 
addition, BAX 930 undergoes two dedicated virus reduction steps: solvent/detergent 
(S/D) treatment and nanofiltration. The final product is lyophilized for intravenous (IV) 
injection. The sterile, lyophilized BAX 930 was stored in 10 mL vials, which were 
reconstituted with 5 mL of sterile water, giving the solution a nominal strength of 
300 U/mL that is stable for 3 hours at room temperature after reconstitution.   BAX 930 
was infused at a rate of 2-4 mL/minute.  In patients receiving regular prophylaxis, there 
was at least a 10-day window between their last prophylactic treatment and their BAX 
930 dose. 
Safety assessments 
Patients were hospitalized for at least 96 hours following investigational product (IP) 
infusion for safety observation and PK assessments. Follow-up visits were scheduled 12 
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days and 30 days (or 6, 9 and 12 days for the two participating adolescents) post-infusion. 
Safety was evaluated through clinical assessment, hematology, serum chemistry, 
urinalysis, coagulation tests, antibodies against ADAMTS-13 or CHO cell protein, viral 
serology, cardiac troponin, D-dimers and seromarkers for brain or renal impairment. 
Adverse events (AEs) were recorded throughout the study, but specifically by the patient 
in a diary, beginning 96 hours post-infusion until the study completion visit.  
ADAMTS-13 and VWF assays 
ADAMTS-13 activity was calculated by analysis of fluorescence over time using the 
synthetic fluorogenic VWF73 peptide substrate (FRETS-VWF73) and a commercially 
available, chromogenic GST-VWF73 based ADAMTS-13-activity ELISA  
(Technozym® ADAMTS-13 Activity ELISA).28;29 ADAMTS-13 antigen was measured 
using a validated sandwich ELISA employing anti-human-ADAMTS-13 
antibodies.30,31,32  VWF:RCo  and VWF:Ag were determined as previously described.33,34   
Analysis of VWF multimers was performed using SDS‐agarose gel electrophoresis 
followed by Western blotting and sensitive luminescence detection.4,35 VWF degradation 
products generated by ADAMTS-13-mediated cleavage were assessed by SDS‐PAGE 
under reducing conditions followed by Western blotting and immunostaining with a 
horseradish peroxidase (HRP)‐labeled polyclonal rabbit antihuman VWF antibody with 
enhanced chemiluminescence detection.4,35,36 
Immunogenicity Assessments 
Total binding antibodies to ADAMTS-13 were measured by ELISA-based assays, 
detecting total Ig (IgG, IgA, IgM).  Neutralizing antibodies to ADAMTS-13 were 
measured using a Bethesda-like approach with the ADAMTS-13 activity assay.37  
Pharmacokinetic assessments 
PK parameters, including area under the concentration-time curve (AUC [h·U/mL]), 
plasma half-life (t1/2 [hours]), clearance (Cl [mL/kg/hours]), mean residence time (MRT 
[hours]), volume of distribution at steady state (Vss [mL/kg]), maximum plasma 
concentration (Cmax [U/mL]) and incremental recovery (IR [U/mL]) were assessed for 
ADAMTS-13 activity and ADAMTS-13 antigen (ADAMTS-13:Ag).  Concentrations 
were measured at standardized time points: within 60 minutes pre-infusion; 15, 30, 60 
minutes and 3, 6, 9, 12, 24, 48, 96, 144, 168, 192, 216, 240, 264 and 288 hours post-
infusion in adults. The two adolescent subjects (16 and 17 years of age) had sparse 
sampling pre-infusion and at 6, 48, 144, 216 and 288 hours post-infusion. The 
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hematology and clinical chemistry assessments, conducted as part of the safety 
assessments (see above), were performed on EDTA anticoagulated whole blood and 
serum, respectively, at the screening visit, just prior to IP infusion, and at regular 
increments up to 288 hours post-infusion.  The hematology panel included platelet counts 
and the clinical chemistry panel included serum LDH, both of which were used for 
assessing the pharmacodynamic effects of BAX 930. 
Statistical analysis 
ADAMTS-13 concentration data were analyzed using a non-compartmental approach and 
individual PK parameter estimates were derived.  Total AUC0‐∞ was calculated by the 
linear trapezoidal rule up to the last quantifiable concentration with a tail area correction. 
Terminal plasma half-life was determined from the terminal rate constant obtained by 
log-linear fitting of a regression line by the least squares deviation method to the last five 
quantifiable concentrations that were above pre-infusion levels. MRT was calculated as 
total area under the moment curve divided by the total area under the curve corrected for 
the duration of the infusion. Systemic clearance (Cl) was calculated as dose per body 
mass (kg) divided by AUC0‐∞. IR was calculated as Cmax divided by dose per body mass.  
To better address the variability in baseline ADAMTS-13 levels, a population PK model 
was also developed.  A two-compartment model with first order elimination and constant 
rate infusion was selected iteratively among different structural and stochastic candidates 
and provided population PK parameter estimates. Individual PK parameters from a non-
compartmental approach and from the population PK model were similar. 
Descriptive statistics were used to assess safety in terms of product-related AEs. 
RESULTS 
Fifteen patients received study drug: three each in the 5 U/kg and 20 U/kg dose cohorts, 
and 9 in the 40 U/kg dose cohort (Figure 1; Table 1); 2 patients in the 40 U/kg cohort 
were adolescents. All patients completed the study. Doses administered were within 
0.3 U/kg of the planned doses, with the exception of one patient who received 47.5 U/kg 
instead of the planned 40 U/kg.   
ADAMTS-13 Activity 
Following the single infusion of BAX 930, dose-related increases in ADAMTS-13 
FRETS-VWF73 concentrations were observed (data from the 40 U/kg cohort shown in 
Figure 2). ADAMTS-13 activity remained quantifiable for 24 hours in the 5 U/kg cohort, 
For personal use only.on October 13, 2017. by guest  www.bloodjournal.orgFrom 
9 
 
for 240 hours in the 20 U/kg cohort, and for the full 288-hour study period in the 40 U/kg 
cohort. ADAMTS-13 activities measured by FRETS-VWF73 and chromogenic assay 
methods were highly comparable (Table 2). 
In the 40 U/kg cohort, the geometric mean of IR was 0.0232 (U/mL·kg/U), mean terminal 
half-life was 59.2 hours and initial half-life was 17.0 hours for ADAMTS-13 activity 
(FRETS-VWF73). ADAMTS-13 activity, Cmax, and total exposures increased 
approximately in proportion to the dose escalations. The geometric mean Cmax was 
0.398 U/mL after 20 U/kg infusion and 0.948 U/mL after 40 U/kg infusion; the geometric 
mean AUC(0-inf) was 19.1 U·h/mL after 20 U/kg infusion and 53.1 U·h/mL after 40 U/kg 
infusion. 
With the more sensitive chromogenic ELISA assay (LLOQ: 0.0073 U/mL compared with 
0.05 U/mL for FRETS-VWF73), low levels of ADAMTS-13 activity were measurable at 
the pre-infusion time point in all patients except one adult and both adolescents.   
Despite the differences in the LLOQ, activity measurements by FRETS-VWF73 and 
chromogenic assay methods were otherwise similar (Table 2). 
ADAMTS-13 Antigen  
ADAMTS-13 antigen (ADAMTS-13:Ag) concentrations at pre-dose (baseline) were low, 
ranging from 0.003 to 0.031 U/mL,  but quantifiable in all but two patients (one patient 
each in the 5 U/kg and 40 U/kg dose cohorts).  Individual post-dose ADAMTS-13:Ag 
levels remained quantifiable in all samples up to the last collection at 288 hours post-dose 
and were higher than baseline (pre-dose) values. 
The geometric mean of ADAMTS-13:Ag Cl was 61.5 mL/h and of Vss was 5300 mL (at 
40 U/kg dose level), suggesting the protein distributed primarily within the intravascular 
compartment.38 There was approximate dose proportionality with respect to Cmax 
(geometric means of 0.323 µg/mL after 20 U/kg infusion and 0.672 µg/mL after 40 U/kg 
infusion) and AUC(0-inf) (geometric means of 18.3 µg·h/mL after 20 U/kg infusion and 
36.0 µg·h/mL after 40 U/kg infusion). 
The PK parameter estimates for ADAMTS-13:Ag were comparable to ADAMTS-13 
activity. Over the 5 U/kg to 40 U/kg dose range, ADAMTS-13:Ag geometric mean Cmax 
increased 5-fold between 5 U/kg and 20 U/kg, and approximately proportional to the dose 
between 20 U/kg and 40 U/kg (2.1-fold) (Table 2). The fold increases in geometric mean 
total exposures (AUC(0-t) and AUC(0-inf)) were approximately proportional to the dose 
increase for both dose level comparisons.  
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ADAMTS-13 Activity and ADAMTS-13 Antigen in Adolescents  
The available concentration data for both ADAMTS-13 activity and ADAMTS-13:Ag, 
did not  suggest any major differences between adolescents and adults.  Despite the low 
number of adolescents in the study (n=2) and reduced sampling per protocol, ADAMTS-
13 activity, IR, t1/2 and AUC were generally within the data ranges for adults treated at 
the same dose level (40 U/kg). The estimated clearances for the two adolescent subjects 
were 64.9 and 54.5 mL/h, respectively, which were within the range observed for adult 
subjects (n=7; range: 44.4 - 115 mL/h). 
Pharmacodynamic Effects 
In addition to the small, intermediate, and large multimeric sizes typically present in 
normal plasma, UL VWF multimers were observed in the samples collected prior to 
dosing, at screening or pre-dose, in all patients, and at most time points post-dose. The 
trend for decreasing large multimers, including UL multimers, and increasing levels of 
the intermediate fraction was observed over the first 12-24 hours post infusion in 
individual profiles at BAX 930 doses of 20 U/kg or 40 U/kg before slowly returning to 
pre-infusion levels over a 288-hour period (Figure 4B). 
Likewise, an apparent dose-dependent effect was seen with the detection of ADAMTS-
13-mediated VWF cleavage products. In the 5 U/kg dose cohort, ADAMTS-13-mediated 
VWF cleavage products were present up to 3 hours post-dose in all patients (100%), up to 
6 hours post-dose in one patient (33.3%), and no longer detectable thereafter (Figure 4A).  
ADAMTS-13-mediated VWF cleavage products were observed over a longer period of 
time at higher dose levels: for 20 U/kg, up to 24 hours post-dose in all patients and up to 
48 hours in two patients (66.7%); for 40 U/kg, up to 48 hours post-dose in all patients and 
as long as 264 hours in one patient (14.3%)  (Figure 4C).    
In addition, the function of VWF to bind platelet GPIb, as measured by the VWF:RCo 
assay, were lower than mean baseline levels at most timepoints across the 3 dose levels 
and decreased by approximately 30% within the first 9 hours.  A modest decrease in LDH 
of 5%-10% relative to baseline was also observed in the first 48 hours post infusion.  In 
addition, although subjects in this study were not experiencing acute manifestations of 
cTTP, there was an increasing trend in the platelet count up to six days after infusion in 
all dosing cohorts (Figure 5).   
Safety 
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BAX 930 was well tolerated in all 15 patients and no patient exhibited anaphylaxis or 
other allergic manifestations. No serious adverse events, adverse events leading to 
discontinuation from the study, nor breakthrough TTP events were seen in the study after 
treatment. Overall, 12 of 15 patients (80.0%) reported at least one temporally emergent 
adverse event (TEAE; see Supplementary Table 1).   Three subjects, all in the 40 U/kg 
BAX 930 cohort (40 U/kg: 3/9 subjects, 33.3%; overall: 3/15 subjects, 20.0%) reported a 
total of five TEAEs considered by the investigators to be  temporally associated with 
BAX 930 infusion: decrease in VWF antigen and VWF activity at 30-minutes post-
infusion, returning to normal activity levels at 1 hour post-infusion (n=1), flatulence 
(n=1), nausea on two separate days (n=1).  No trends were observed over time or among 
the three dose cohorts in the laboratory parameters, vital sign assessments, ECG 
measurements, or physical examination. 
Immunogenicity Evaluation 
All anti-ADAMTS-13 neutralizing antibody results were <0.6 BU/mL across the 
three dose cohorts and at all three scheduled time points; i.e., screening, infusion pre-
dose, and at study completion, day 28 ± 3 days. None of the 15 patients who received 
BAX 930 exhibited anti-ADAMTS-13 binding antibodies at any time in the study. 
Similarly, all patients tested negative for anti-CHO protein antibodies at all timepoints.  
 
DISCUSSION  
Recombinant ADAMTS-13 potentially offers a novel option for the treatment of cTTP, 
eliminating many of the risks associated with products derived from human plasma and 
facilitating the introduction of more precise and individualized dosing regimens.24,39-43 In 
our prospective, dose escalating clinical trial we investigated the safety, tolerability and 
PK of BAX 930 infused for the first time in humans.  
BAX 930 was expected to behave in the same way as endogenous ADAMTS-13, as 
demonstrated in several non-clinical in vitro and in vivo studies. In current clinical 
practice, infusions of 10-20 mL/kg FFP are recommended for treating acute episodes or 
prophylaxis of cTTP.44-46 As such, a low dose of 5 U/kg, an intermediate dose of 20 U/kg, 
and a high dose of 40 U/kg BAX 930 were chosen for this study. The 40 U/kg dose has 
been calculated to correspond to doses of ADAMTS-13 typically administered during 
single volume plasma exchange sessions.47 
As would be expected in this cTTP patient population, pre-dose baseline levels of 
ADAMTS-13:Ag and ADAMTS-13 activity (assessed by both  FRETS-VWF73 and 
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chromogenic ELISA assays) were very low or below the lower limit of quantitation  
(LLOQ).  Immediately following infusion of all doses of BAX 930 there was an increase 
in individual ADAMTS-13:Ag and activity observed,  reaching a maximum within 1 hour 
post infusion. Similar ADAMTS-13:Ag, ADAMTS-13 FRETS-VWF73, and ADAMTS-
13 activity ELISA profiles suggest good correlation between protein concentrations and 
activity. No apparent differences were observed for ADAMTS-13 activity and 
ADAMTS-13:Ag between adolescents (n=2) and adults (n=7), treated with the same 
BAX 930 doses. 
Overall, there was evidence suggesting dose proportionality with respect to AUC(0-inf) and 
Cmax  (Table 2; Figure 3). The change in the geometric mean Cmax for 5 U/kg to 20 U/kg 
was approximately 5-fold and approximately 2.4-fold for 20 U/kg to 40 U/kg. Greater 
increases were observed for geometric mean AUC(0-inf) (47-fold for 5 U/kg to 20 U/kg and 
3.1-fold for 20 U/kg to 40 U/kg), which could be attributable to concentrations falling 
below the LLOQ at lower doses. Available data for AUC(0-inf) showed an approximately 
2.8-fold increase in exposure for dose increases from 20 U/kg to 40 U/kg. Available data 
at the 20 U/kg and 40 U/kg dose levels show no major changes in Cl, Vss, t1/2, and MRT(0-
inf) with increasing dose. 
PK parameters derived from the non-compartmental and population PK approaches were 
consistent.  In the population PK model, a shorter initial half-life was observed followed 
by a longer terminal half-life. Whether the initial phase is due to VWF binding, 
consumption of ADAMTS-13 activity or distribution to another physiologic compartment 
remains to be determined. 
In addition to the PK results, evidence of pharmacodynamic activity was observed. With 
escalating BAX 930 doses, prolonged detectable ADAMTS-13-mediated VWF cleavage 
products were present, in line with dose-related increases of ADAMTS-13:Ag and 
activity. Specifically, detectable ADAMTS-13-mediated VWF cleavage products were 
present in all patients (100%) and up to 48 hours following the highest dose, 40 U/kg. 
Patients with cTTP typically exhibit UL molecular weight forms of VWF at baseline 
consistent with the severe reduction in ADAMTS-13 activity. A trend for decreasing 
large multimers, a fraction of which also included UL multimers, and increasing levels of 
the intermediate fraction was observed over the first 24 hours post infusion in individual 
profiles at BAX 930 doses of 20 U/kg or 40 U/kg. In addition, over the first 9 hours, the 
mean postdose VWF:RCo levels decreased by approximately 30%.  There was also an 
increase in the platelet count in all dosing groups. Taken together, these findings provide 
evidence of in vivo ADAMTS-13 activity following BAX 930 administration. 
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This study demonstrated that the protein antigen and activity PK parameters of BAX 930 
were comparable to those estimated from previous studies of ADAMTS-13 administered 
to cTTP patients as a constituent of FFP. Furlan et al24 reported limited PK data in 
patients treated with FFP and demonstrated that the recovery was nearly 100% and the 
half-life was 2.1-3.3 days. Similar results were reported by Fujimura et al.43  The 
comparability of plasma-derived and recombinant ADAMTS-13 pharmacokinetics 
suggests that dosing regimens in future studies of the long-term safety and efficacy of 
BAX930 can be modeled on the clinical experiences with plasma-based regimens.  No 
patients developed an inhibitor to ADAMTS-13 during this single dose study. The lack of 
an apparent immune response will need to be confirmed in the upcoming pivotal study in 
which patients will be repeatedly exposed to BAX 930 for approximately one year. 
In conclusion, BAX 930 appeared to be safe and well tolerated over a dose range of 5 to 
40 U/kg in cTTP patients, and there was no evidence of an immune response to BAX 930 
following a single infusion. The activity PK parameters were comparable to those 
estimated from FFP studies and demonstrated approximate dose proportionality with 
respect to Cmax and AUC. Finally, there was evidence for BAX 930 activity in vivo, 
including effects on VWF multimers, platelet count, and serum LDH. These data provide 
the basis for proceeding to a phase 3 pivotal study in cTTP utilizing previously 
anticipated prophylactic and treatment dosing regimens. 
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1 22 F White 15 Prophylaxis 5 U/kg 106* 294* 
2 28 M White 24 On Demand 5 U/kg 166 136 
3 35 M White 29 Prophylaxis 20 U/kg 154 170 
4 21 F Asian <1 Prophylaxis 40 U/kg 167 151 
5 24 F Asian 17 Prophylaxis 20 U/kg 220 142 
6 25 M White 2 Prophylaxis 40 U/kg 190+ 159 
7 33 F White 20 Prophylaxis 40 U/kg 223 165 
8 32 F White 10 On Demand 40 U/kg 221 146 
9 40 M White 16 Prophylaxis 40 U/kg 216 125 
10 41 F White 19 On Demand 5 U/kg 348 130 
11 39 F White 36 Prophylaxis 20 U/kg 252 259* 
12 16 M White 14 Prophylaxis 40 U/kg 214 153 
13 17 F White <1  Prophylaxis 40 U/kg 353 140 
14 33 M White 26 Prophylaxis 40 U/kg 273 122+ 
15 30 M Black 14 Prophylaxis 40 U/kg 297 185 
Note: Table has been anonymized by permutation of the following columns: age and age at diagnosis. 
* Abnormal 
+ Baseline values provided; screening values not available 
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Table 2. Summary of key plasma ADAMTS-13 FRETS-VWF73 pharmacokinetic 
parameters in adults 
Pharmacokinetic Parameters 
Median (range)  
5 U/kg 
(n = 3)  
20 U/kg 
(n = 3) 
40 U/kg 
(n = 7) 
FRETS-VWF73 
IR, U/mL*kg/U 0.0154 (0.0125-0.0187)  0.0181 (0.0153-0.0290) 0.0228 (0.0185-0.0290) 
Cmax, U/mL 0.075 (0.065-0.100) 0.361 (0.300-0.583) 0.941 (0.737-1.158) 
tmax, h [a] 1.00 (0.52-1.00) 0.33 (0.25-0.53) 0.37 (0.22-0.58) 
AUC(0-inf), U*h/mL  ND[b] 18.1 (15.4-24.9) 52.3 (41.3-85.4) 
AUC(0-t), U*h/mL  0.388 (0.0528-1.68) 14.9 (11.5-21.1) 46.5 (37.2-78.8) 
t1/2, h  ND[b] 36.5 (29.5-69.2) 66.9 (44.1-77.8) 
MRT(0-inf), h ND[b] 48.876 (43.55-93.87) 92.468 (55.71-124.01) 
Cl, mL/h ND[b] 64.8 (53.3-100) 59.3 (44.4-115) 
Vss, mL  ND[b] 4900 (2820-5000) 5250 (4100-6830) 
Technozym 
IR, U/mL*kg/U 0.0170 (0.0160-0.0179) 0.0157 (0.0136-0.0254) 0.0212 (0.0144-0.0261) 
Cmax, U/mL 0.087 (0.083-0.091) 0.308 (0.272-0.512) 0.844 (0.574-1.039) 






AUC(0-inf), U*h/mL  6.68 (4.32-17.4) 21.8 (18.3-25.8) 45.6 (40.6-89.1) 
AUC(0-t), U*h/mL  6.39 (4.26-8.43) 20.6 (15.9-25.4) 43.8 (37.3-80.4) 
t1/2, h  66.2 (44.2-238) 64.4 (46.9-69.8) 62.6 (46.5-77.0) 
MRT(0-inf), h 90.401 (69.41-383.36) 90.663 (65.38-114.38) 78.382 (63.54-124.58) 
Cl, mL/h 51.8 (13.3-88.9) 54.7 (44.1-96.8) 68.4 (45.7-111) 
Vss, mL  5090 (4680-6170) 6260 (4000-6330) 6010 (3130-8700) 
ADAMTS13 Antigen 
IR, µg/mL*kg/µg 0.0176 (0.0171-0.0194) 0.0220 (0.0180-0.0354) 0.0247 (0.0205-0.0328) 
Cmax, µg/mL 0.066 (0.062-0.066) 0.296 (0.238-0.480) 0.655 (0.549-0.879) 






AUC(0-inf), µg*h/mL  4.14 (4.14-5.90) 18.1 (16.8-20.2) 33.4 (29.4-67.8) 
AUC(0-t), µg*h/mL  4.05 (3.59-4.49) 16.4 (15.6-19.9) 30.4 (28.3-61.0) 
t1/2, h  93.9 (56.2-122) 48.0 (47.0-82.3) 70.4 (50.9-86.3) 
MRT(0-inf), h 131.365 (75.45-192.16) 67.210 (62.37-128.74) 87.134 (68.83-125.51) 
Cl, mL/h 58.3 (27.3-64.8) 40.1 (35.8-83.1) 61.8 (41.9-116) 
Vss, mL  5240 (4400-8510) 4610 (2690-5180) 4760 (3650-8150) 
AUC(0-inf) = Area under the plasma-time concentration curve from zero to infinity;  
AUC(0-t) = Area under the plasma-time concentration curve from zero to the last measured timepoint;  
Cl = Systemic clearance; Cmax = Maximum concentration following infusion;  
IR = Incremental recovery; max = Maximum; min = Minimum; MRT = Mean residence time; 
ND = not determined; t1/2 = Half-life; tmax: Minimum time to reach Cmax;  
Vss = Volume of distribution at steady state 
[a]
 Median (min - max) 
[b]
 n = 1 for AUC(0-inf), t1/2, MRT(0-inf), Cl, and Vss 
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Figure 1. Study population disposition. 
Figure 2. Observed ADAMTS-13 activity over time. 
ADAMTS-13 activity in plasma was measured at baseline and at time points up to 288 hours 
using the FRETS-VWF73 assay following a 40 U/kg administration of BAX 930. 
Figure 3. Predicted PK Estimates from Two-Compartment Model. 
Predicted FRETS-VWF73 activity time profiles are depicted based on a two-compartmental 
model according to linear and log concentrations.  Both display approximate dose 
proportionality. The use of the two compartment (n=9) and the non-compartmental (NCA; n=7) 
models yield comparable results. 
Figure 4. VWF Structural Analyses pre- and post-infusion of BAX 930. 
(A) Representative SDS-agarose gel pattern of pretreatment TTP plasma depicting ultralarge, 
large, intermediate, and small size VWF multimers. 
(B) The proportions of intermediate and large/ultralarge multimers of plasma VWF were 
estimated from SDS-agarose gels at various times prior to and following infusion of 40 U/kg 
BAX 930. The observed concentration of large and ultralarge multimers tended to decrease in all 
treated patients in the first 12 hours, before gradually returning to pre-infusion levels. 
(C) Time course of the 176 kDa ADAMTS-13 VWF cleavage product following administration 
of 5 U/kg, 20 U/kg, and 40 U/kg BAX 930. High levels of detectable VWF cleavage products are 
apparent just after dosing, which gradually return to pre-infusion levels in a dose-related manner. 
Figure 5. Changes in platelet counts following BAX 930 administration. 
Changes in mean platelet counts over time are depicted following administration of 5 U/kg, 20 
U/kg, and 40 U/kg of BAX 930. An increasing trend in platelet levels was observed in all dosing 
cohorts. 
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Figure 2. Observed ADAMTS-13 activity over time.   ADAMTS-13 activity in plasma was 
measured at baseline and at time points up to 288 hours using the FRETS-VWF73 assay 
following a 40 U/kg administration of BAX 930. 
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Figure 3.   Predicted PK Estimates from Two-Compartment Model 
Predicted FRETS-VWF73 activity time profiles are depicted based on a two-compartmental 
model according to linear and log concentrations.  Both display approximate dose 
proportionality. The use of the two compartment (n=9) and the non-compartmental (NCA; n=7) 
models yield comparable results. 
Parameter, unit Two Compartment NCA model 
Cmax, U/mL 0.867 0.957 
IR, (U/mL)/(U/kg) 0.021 0.0234 
Terminal half-life, h 57.087 60.5 
MRT, h 77.593 87.656 
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Figure 4. VWF Structural Analyses pre- and post-infusion of BAX 930  
(A) Representative SDS-agarose gel pattern of pretreatment TTP plasma depicting ultralarge, large, intermediate, 
and small size VWF multimers.  
(B) The proportions of intermediate and large/ultralarge multimers of plasma VWF were estimated from SDS-
agarose gels at various times prior to and following infusion of 40 U/kg BAX 930. The observed concentration of 
large and ultralarge multimers tended to decrease in all treated patients in the first 12 hours, before gradually 
returning to pre-infusion levels. 
(C)  Time Course of the 176 kDa ADAMTS-13 VWF cleavage product following administration of 5 U/kg, 20 U/kg, 
and 40 U/kg BAX 930. High levels of detectable VWF cleavage products are apparent just after dosing, which 
gradually return to pre-infusion levels in a dose-related manner. 
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Figure 5.  Changes in platelet counts following BAX 930 administration 
Changes in mean platelet counts over time are depicted following administration of 5 U/kg, 20 U/kg, and 40 U/kg of 
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